Unaudited Financial results for the quarter ended June 30, 2026

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com July 22, 2026 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Limited. (Scrip Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code: DRREDDY) Dear Sir/Madam, Sub: Outcome of Board Meeting held on July 22, 2026 Pursuant to Regulations 30 and 33 and other applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) and in furtherance to our letter dated June 22, 2026, we would like to inform that the Board of Directors of the Company, at their meeting held today, i.e. July 22, 2026, have inter alia considered and approved the following: 1. Unaudited Financial Results for the quarter ended June 30, 2026: a. Unaudited Consolidated Financial Results of the Company for the quarter ended June 30, 2026, prepared in compliance with International Financial Reporting Standards (IFRS) as issued by International Accounting Standards Board (IASB); b. Press Release on Unaudited Financial Results of the Company for the quarter ended June 30, 2026; c. Unaudited Consolidated Financial Results of the Company for the quarter ended June 30, 2026, as per Indian Accounting Standards; d. Unaudited Standalone Financial Results of the Company for the quarter ended June 30, 2026, as per Indian Accounting Standards; and e. Limited Review Reports of the Statutory Auditors on the Unaudited Standalone and Consolidated Financial Results as mentioned above. 2. Appointment of Senior Management Personnel Pursuant to the recommendation of the Nomination, Governance and Compensation Committee, the Board of Directors of the Company, at their meeting held today, approved the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel of the Company, and her induction as a Member of the Management Council, effective July 22, 2026. The updated list of the Company's Senior Management Personnel, reflecting the above appointment, is enclosed as Annexure A1. 3. Appointment of M/s Deloitte Haskins & Sells, LLP as Independent Registered Public Accounting Firm This is in continuation of our letter dated May 12, 2026, wherein the Company had informed that it has appointed M/s Deloitte Haskins & Sells, LLP, (Firm Registration No. 117366W/W-100018), as the Statutory Auditors of the Company, in terms of the provisions of Companies Act, 2013, for a term of five consecutive years, commencing from the conclusion of the 42nd AGM till the conclusion of the 47th AGM, subject to the approval of the shareholders at the ensuing AGM. We further wish to inform that to align with the above and basis the recommendation of the Audit Committee, the Board of Directors have approved the appointment of M/s Deloitte Haskins & Sells, LLP, as the Independent Registered Public Accounting Firm of the Company for the purpose of auditing the financial statements of the Company to be included in the Company’s Annual Report on Form 20-F and reviewing the interim financial statements to be filed with the U.S. Securities and Exchange Commission on Form 6-K. The disclosure required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed as Annexure A and B. The Board Meeting commenced at 2:30 p.m. IST and concluded at 4:03 p.m. IST. This is for your information and records. Thanking you. Yours faithfully, For Dr. Reddy’s Laboratories Limited K Randhir Singh Company Secretary, Compliance Officer & Head-CSR Encl: as above Dr. Raddy's Laboratories Ltd. Dr.Reddy's ~;• 8-2-337, Road No. 3, Banjara Hills, Hyderabad -500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com DR. REDDY'S LABORATORIES LIMITED Unaudited consolidated financial results of Dr. Reddy's Laboratories Limited and its subsidiaries for the quarter ended 30 June 2026 prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) All amounts in Indian Rupees millions Quarter ended Year ended Particulars 30.06.2026 31.03.2026 30.06.2025 31.03.2026 (Unaudited) (Audited) (Unaudited) (Audited) 1 Revenues 80,705 75,162 85,452 335,933 2 Cost of revenues 43,165 41,471 36,825 158,669 3 Gross profit (1 -2) 37,540 33,691 48,627 177,264 4 Selling, general and administrative expenses 28,820 27,762 25,647 106,763 5 Research and development expenses 5,766 5,463 6,244 24,058 6 Impairment of non-current assets, net 15 2,586 - 3,519 7 Other income, net (845) (3,445) (739) (7,627) Total operating expenses 33,756 32,366 31,152 126,713 8 Results from operating activities [(3) -(4 + S + 6 + 7)] 3,784 1,325 17,475 50,551 Finance income 2,989 1,677 2,400 7,870 Finance expense (1,255) (1,057) (830) (3,738) 9 Finance income, net 1,734 620 1,570 4,132 10 Share of profit of equity accounted investees, net of tax 8 46 2 134 11 Profit before tax (8 + 9 + 10) 5,526 1,991 19,047 54,817 12 Tax expense, net 1,178 (214) 4,951 12,351 13 Profit for the period/year (11 -12) 4,348 2,205 14,096 42,466 Attributable to: Equity holders of the parent company 4,435 2,201 14,178 42,850 Non-controlling interests (87) 4 (82) (384) 14 Earnings per equity share attributable to equity shareholders of parent Basic earnings per share of Re. I/-each 5.32 2.64 17.04 51.48 Diluted earnings per share of Re. I/-each 5.32 2.64 17.02 51.42 (Not annualised) (Not annualised) (Not annualised) Dr.Reddy's ~;• Segment information All amounts in Indian Rupees millions Quarter ended Year ended Particulars 30.06.2026 31.03.2026 30.06.2025 31.03.2026 (Unaudited) (Audited) (Unaudited) (Audited) Segment wise revenue and results: 1 Segment revenue: a) Global Generics 71,993 65,802 75,620 299,033 b) Pharmaceutical Services and Active Ingredients 10,527 ll,075 9,709 42,043 c) Others 193 236 1,651 2,127 Total 82,713 77,113 86,980 343,203 Less: Inter-segment revenues 2,008 1,951 1,528 7,270 Net revenues 80,705 75,162 85,452 335,933 2 Segment results: Gross profit from each segment a) Global Generics 37,123 31,809 46,086 169,698 b) Pharmaceutical Services and Active Ingredients 381 1,817 1,082 5,984 c) Others 36 65 1,459 1,582 Total 37,540 33,691 48,627 177,264 Less: Selling and other un-allocable expenditure, net of other 32,014 31,700 29,580 122,447 income Total profit before tax 5,526 1,991 19,047 54,817 Global Generics segment includes operations of Biologics business. Inter-segment revenues represent sale from Pharmaceutical Services and Active Ingredients to Global Generics at cost. Segmental capital employed As certain assets of the Company including manufacturing facilities, development facilities, treasury assets and liabilities are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table. Notes: I The above Statement of unaudited consolidated financial results of Dr. Reddy's Laboratories Limited (the "parent company"), together with its subsidiaries (collectively, the "Company"), joint ventures and associates, have been prepared in accordance with recognition and measurement principles of IAS 34 as issued by the International Accounting Standards Board (IASB), and presented as per the format of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and were reviewed and recommended by Audit Committee and approved by the Board of Directors at their meetings held on 22 July 2026. The Auditors have carried out a limited review on the unaudited consolidated financial [Showing first 8,000 characters — download PDF for full document]